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Summary
 
We have examined the role of the immunomodulatory cytokine transforming growth factor
(TGF)-
 
b
 
 in the resolution and pathology of malaria in BALB
 
/
 
c mice. Circulating levels of
TGF-
 
b
 
, and production of bioactive TGF-
 
b
 
 by splenocytes, were found to be low in lethal in-
fections with 
 
Plasmodium berghei
 
. In contrast, resolving infections with 
 
P. chabaudi chabaudi
 
 or 
 
P.
yoelii
 
 were accompanied by significant TGF-
 
b
 
 production. A causal association between the
failure to produce TGF-
 
b
 
 and the severity of malaria infection was demonstrated by treatment
of infected mice with neutralizing antibody to TGF-
 
b
 
, which exacerbated the virulence of 
 
P.
berghei
 
 and transformed a resolving 
 
P. chabaudi chabaudi
 
 infection into a lethal infection, but had
little effect on the course of 
 
P. yoelii
 
 infection. Parasitemia increased more rapidly in anti–TGF-
 
b
 
–treated mice but this did not seem to be the explanation for the increased pathology of in-
fection as peak parasitemias were unchanged. Treatment of 
 
P. berghei
 
–infected mice with re-
combinant TGF-
 
b
 
 (rTGF-
 
b
 
) slowed the rate of parasite proliferation and prolonged their
survival from 15 to up to 35 d. rTGF-
 
b
 
 treatment was accompanied by a significant decrease in
serum tumor necrosis factor 
 
a
 
 and an increase in interleukin 10. Finally, we present evidence
that differences in TGF-
 
b
 
 responses in different malaria infections are due to intrinsic differ-
ences between species of malaria parasites in their ability to induce production of TGF-
 
b
 
.
Thus, TGF-
 
b
 
 seems to induce protective immune responses, leading to slower parasite growth,
early in infection, and, subsequently, appears to downregulate pathogenic responses late in in-
fection. This duality of effect makes TGF-
 
b
 
 a prime candidate for a major immunomodulatory
cytokine associated with successful control of malaria infection.
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E
 
xperimental infection of mice with various species and
strains of rodent malaria parasites has facilitated dissec-
tion of the immunological events associated with both par-
asite clearance and the pathology of malaria infection. Res-
olution of a primary infection with the nonlethal parasites
 
Plasmodium yoelii 17X
 
, 
 
P. chabaudi chabaudi
 
, and 
 
P. chabaudi
adami
 
 is dependent on IFN-
 
g
 
 (1–3); TNF-
 
a
 
 and IFN-
 
g
 
 act
synergistically to optimize nitric oxide production (4, 5),
which is involved in parasite killing (6). The difference be-
tween lethal and nonlethal murine malarias can be ex-
plained, at least in part, by the ability of the mice to mount
an early IFN-
 
g
 
 response (7, 8) and
 
/
 
or an early TNF-
 
a
 
 re-
sponse (2); this may, in turn, be linked to early IL-12 pro-
duction (4).
However, proinflammatory cytokines can also contrib-
ute to the pathology of rodent malaria. In mice infected
with lethal strains of 
 
P. berghei
 
, neutralization of IFN-
 
g
 
 (9),
or blocking IFN-
 
g
 
 signaling by disruption of the IFN-
 
g
 
 re-
ceptor gene (10), delays or completely abrogates mortality,
whereas overproduction, or sustained production, of IFN-
 
g
 
or TNF-
 
a
 
 predisposes to severe pathology in both 
 
P. cha-
baudi chabaudi– and P. vinckei
 
–infected mice (2, 9, 11).
Thus, it seems that an early proinflammatory cytokine re-
sponse mediates protective immunity, whereas a late re-
sponse contributes to pathology.
In nonlethal infections, inflammatory responses may be
actively downregulated by antiinflammatory cytokines. One
candidate cytokine is IL-10. IL-10–deficient mice infected
with 
 
P. chabaudi chabaudi
 
 AS showed increased mortality
compared to normal littermates, even though peak para-
sitemias were not significantly different (12). However,
similar IL-10–deficient mice infected with nonlethal 
 
P.
yoelii
 
 or with the relatively avirulent 
 
P. chabaudi adami
 
556KA showed the same response to infection as wild-type
mice (1). In 
 
P. berghei
 
 ANKA infections, susceptible strains
of mice show increased expression of IFN-
 
g
 
 mRNA and
reduced expression of mRNA for TGF-
 
b
 
 compared to re-
sistant strains of mice (13), suggesting that TGF-
 
b
 
 may play
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a role in downregulation of pathogenic proinflammatory
cytokines.
TGF-
 
b
 
, which is produced by a wide range of cells in-
cluding macrophages and T cells (14), has both pro- and
antiinflammatory properties, depending on its environment
and concentration (15). Importantly, TGF-
 
b
 
 suppresses
production of TNF-
 
a
 
 and nitric oxide from macrophages
(16, 17) and suppresses production of IFN-
 
g
 
 and TNF-
 
a
 
from NK cells (18). It has recently been proposed that these
effects may be mediated via enhanced IL-10 production by
macrophages (19), eventually leading to a shift in the im-
mune response away from a Th1-like response and towards
a Th2-like response (20).
Although murine malaria models do not replicate all the
features of human malaria, there are strong correlations be-
tween the patterns of cytokine production seen in infected
mice and humans. In certain circumstances, IFN-
 
g
 
 re-
sponses are associated with protective immunity to 
 
P. falci-
parum
 
 (21, 22), but IFN-
 
g
 
 levels are higher in clinical cases
of malaria than in asymptomatic cases (23, 24), and there is
evidence of a causal association between IFN-
 
g
 
 secretion
and fever (25). Similarly, TNF-
 
a
 
 mediates parasite killing
by macrophages (26, 27), but severe 
 
P. falciparum
 
 malaria is
accompanied by high levels of circulating TNF-
 
a
 
 (28, 29),
and polymorphisms within the promoter region of the
TNF-
 
a
 
 gene have been linked to an increased risk of cere-
bral malaria (30). Together, these observations indicate that
in humans, as in mice, there is a critical balance to be found
in terms of the inflammatory response to malaria infection.
Understanding how this balance is maintained may provide
new approaches to control of malarial parasitemia and pre-
vention of severe disease.
To investigate the role of TGF-
 
b
 
 in the pathogenesis
of malaria, we have measured TGF-
 
b
 
 production from
splenic mononuclear cells of mice infected with both non-
lethal (
 
P. chabaudi chabaudi
 
 A
 
/
 
J and 
 
P. yoelii
 
 17X) and lethal
(
 
P. berghei
 
 NK65) rodent malarias and have examined the
effect of neutralizing antibodies to TGF-
 
b
 
, or recombinant
TGF-
 
b
 
, on the course of malaria infections in vivo. We
conclude that levels of TGF-
 
b
 
 are inversely correlated with
the severity of malaria infections in mice and that TGF-
 
b
 
plays an essential role in downregulating the production of
potentially pathogenic proinflammatory cytokines. Fur-
thermore, differences in TGF-
 
b
 
 production in mice in-
fected with different 
 
Plasmodium
 
 species appear to be due to
intrinsic differences in the ability of parasite antigens to in-
duce TGF-
 
b
 
 production from macrophages.
 
Materials and Methods
 
Parasites
 
P. berghei
 
 (NK65), 
 
P. chabaudi chabaudi
 
 (A
 
/
 
J), and 
 
P. yoelii
 
 (17X)
were obtained from Professor David Walliker, WHO Malaria
Repository, University of Edinburgh, Edinburgh, UK. 
 
P. berghei
 
is highly virulent in mice (31), susceptibility to 
 
P. chabaudi cha-
baudi
 
 varies between strains of inbred mice but resolves spontane-
ously in BALB
 
/
 
c mice (32), and 
 
P. yoelii
 
 is generally avirulent, al-
 
though a lethal strain (17XL
 
/
 
YM) has been derived from the
avirulent 17X strain (33). Cryopreserved parasites were thawed,
injected intraperitoneally into BALB
 
/
 
c mice, and maintained by
regular passage into naive mice.
Parasitized mouse erythrocytes (20–40% parasitemia) were puri-
fied by layering onto 72% Percoll (Pharmacia Biotech AB, Upp-
sala, Sweden) and centrifuged at 2,300 rpm for 15 min. Schizonts
were recovered from the gradient interface and washed in RPMI
(GIBCO BRL, Paisley, UK). 
 
Mice
 
4–6-wk-old male BALB
 
/
 
c mice were obtained from Harlan
(Oxford, UK). The drinking water of experimental mice was sup-
plemented with 2.5 g
 
/
 
liter 
 
p
 
-aminobenzoic acid to ensure that par-
asite growth was not inhibited by a lack of essential nutrients (34).
 
Experimental Malaria Infections
 
Mice were infected with either 10
 
4
 
 (
 
P. berghei
 
) or 10
 
5
 
 (
 
P.
berghei
 
, 
 
P. chabaudi chabaudi
 
, or 
 
P. yoelii
 
) parasite-infected erythro-
cytes, in 100 
 
m
 
l of PBS by intraperitoneal injection. Control mice
received an equal number of uninfected erythrocytes. Parasitemia
was monitored every second day by Giemsa-stained thin blood
smears obtained from tail bleeds.
For estimation of cytokine production from spleen cells, and to
obtain serum for cytokine assays, test and control mice were
killed at regular intervals; blood was obtained by venepuncture
and spleens were retained for cellular assays. Blood was allowed to
clot and serum was stored at 
 
2
 
20
 
8
 
C until required.
To examine the effect of neutralization of TGF-
 
b
 
 on the
course of malaria infection, mice were each given 50 
 
mg of an
IgG1 monoclonal antibody to TGF-b, which neutralizes all three
TGF-b isoforms (1835-01; Genzyme Diagnostics, Cambridge,
MA), by intraperitoneal injection 1 d before malaria infection and
on days 2, 5, and 7 after infection. Control mice received 50 mg
of polyclonal mouse IgG1 (Serotec, Oxford, UK).
To examine the effect of increased TGF-b levels in malaria-
infected mice, mice were infected with P. berghei and given either
5 ng or 20 ng of recombinant TGF-b1 (R&D Systems Europe
Ltd., Abingdon, UK) in 100 ml of PBS by intraperitoneal injec-
tion on the day of infection and then daily for another 4 d. Con-
trol mice received PBS only.
Mononuclear Cell Cultures
Mononuclear cells were obtained from macerated spleens by
centrifugation over a 5-ml gradient of mouse lymphocyte separa-
tion medium (Harlan-Seralab, Loughborough, UK). After wash-
ing in RPMI, cells were resuspended in complete medium
(RPMI containing 2 g/liter NaCO2, 2mM l-glutamine, 100 U/ml
penicillin, and 100 mg/ml streptomycin, all from ICN Biomedi-
cals, Costa Mesa, CA) and allowed to adhere to plastic petri
dishes coated with mouse serum for 90 min at 378C. Nonadher-
ent cells were washed away, adherent cells (z90% macrophages
and z10% lymphocytes) were recovered by incubation for 30
min at 48C in calcium- and magnesium-free saline (HBSS; Sigma
Chemical Co., St. Louis, MO) and counted, and 2.5 3 106 ad-
herent cells were added to each well of a 48-well microtiter plate.
Cells were cultured in 350 ml of complete medium at 378C in 5%
CO2 in air for up to 48 h either without further stimulation or in
the presence of 5 3 105 live malaria parasites, uninfected red
blood cells, or the mitogen Con A (5 mg/ml; Sigma Chemical
Co.). Cell culture supernatants were collected and stored at
2208C until required.41 Omer and Riley
TGF-b Bioassay
This assay, based on the ability of TGF-b to inhibit the in vitro
proliferation of mink lung epithelial cells (Mv-I-Lu; 35), mea-
sures the combined effects of all TGF-b isoforms. Mv-I-Lu cells
(ATCC clone CCL64; European Collection of Cell Cultures,
Wiltshire, UK) were maintained by weekly passage in Eagle’s
minimum essential medium (Sigma Chemical Co.) supplemented
with 0.1 M nonessential amino acids, 1 mM sodium pyruvate, 2
mM l-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 10% heat-inactivated fetal bovine serum (FBS; all from Sigma
Chemical Co.). Cells were detached from the culture flask by in-
cubation at 378C with 0.5% trypsin/5.3 mM EDTA, washed, and
resuspended in complete medium, containing 6% serum substi-
tute (Ultroser; GIBCO BRL) instead of FBS, at 2 3 104 cells/ml.
104 cells, in a volume of 50 ml, were aliquoted into each well of a
96-well, flat-bottomed microculture plate and left to adhere for 2 h.
Culture supernatants were tested for TGF-b activity either
with or without prior acid-activation. Acid-activation converts
the inactive precursor form of TGF-b into biologically active
TGF-b, allowing total TGF-b to be measured; in contrast, only
biologically active TGF-b is measured in non–acid-activated
samples. For acid activation, 10 ml 1 M HCl was added to 100 ml
supernatant, incubated at 48C for 30 min, and neutralized by
dropwise addition of 20 ml 1 M NaOH. 50 ml of test sample or
TGF-b1 standard (recombinant murine TGF-b1, IC50 0.03–0.05
ng/ml; Sigma Chemical Co.) and 50 ml fresh medium (with 6%
Ultroser) were added to triplicate wells of Mv-I-Lu cells and in-
cubated for 48 h at 378C in 5% CO2 in air; [3H-]thymidine (0.5
mCi/well; Amersham Life Sciences, Little Chalfont, UK) was
added for the last 18 h of culture. For cell harvesting, cells were incu-
bated with 50 ml trypsin/EDTA for 15–30 min at 378C and then
harvested onto glass fiber filters; incorporation of 3H was assessed
by liquid scintillation counting. Concentration of TGF-b in the
sample was calculated by reference to the percentage inhibition of 3H
incorporation caused by different concentrations of the TGF-b1
standard. The specificity of the assay was confirmed by blocking the
inhibition of cell growth with a neutralizing monoclonal antibody
to all isoforms of murine TGF-b (20 mg/ml; 1D11.16; Genzyme).
ELISAs
TGF-b1. A sandwich ELISA was used to measure total
TGF-b1 (latent and mature) in mouse serum (36). Plates were
coated overnight with 4 mg/ml monoclonal anti-TGF-b1 anti-
body (clone MCA797, Serotec, Oxford, UK), washed, blocked
with 4% bovine serum albumin (BSA; Sigma Chemical Co.) and
samples (100 ml) added to duplicate wells and incubated at 378C
for 1 h. After washing, bound TGF-b1 was detected with bioti-
nylated, polyclonal chicken antibody to mouse TGF-b (2 mg/ml)
(R&D Systems) and streptavidin-peroxidase (Sigma) and visualized
with 2,29-azino-bis(-3ethylbenzthiazoline-6-sulfonic acid) (ABTS,
Sigma) and hydrogen peroxide (Sigma). A standard curve was
generated using rTGF-b1 (R&D Systems). The assay was sensitive
over a range of TGF-b1 concentrations from 0.01 to 100 ng/ml.
IFN-g, TNF-a, IL-10, and IL-4. Sandwich ELISAs were
conducted with commercial reagents (PharMingen, San Diego,
CA) according to the manufacturer’s instructions. Briefly, plates
were coated with 2 mg/ml of capture antibody and blocked with
4% BSA in PBS containing 0.05% Tween 20 (Sigma). Samples or
standards, 100 ml, were added to duplicate wells and incubated at
378C for 1 h. Plates were washed and bound cytokine was de-
tected with 2 mg/ml biotinylated antibody and streptavidin-per-
oxidase. Plates were developed as described above. Cytokine
standards (PharMingen) were tested over the following ranges:
IFN-g, 1.5 to 3,200 U/ml; TNF-a, 0.01 to 1,500 ng/ml; IL-10,
0.04 to 1,500 ng/ml; IL-4, 20 to 5,000 pg/ml.
Statistical Analysis
Differences between the means, of groups of five mice, were
determined by Student’s t test.
Results
TGF-b Production during Fatal and Resolving Murine 
Malaria Infections
After infection with either 104 or 105 infected erythro-
cytes, P. berghei infection was universally fatal by day 20
(104) or days 13–15 (105) after infection. In contrast, P.
yoelii and P. chabaudi chabaudi infections resolved spontane-
ously; parasitemia peaked around days 14–16 and was
cleared by day 23 after infection.
Mice were killed at various time points after infection
and spleens were removed. Spontaneous production of
both latent and bioactive TGF-b by splenic mononuclear
cells was assessed by bioassay. In P. berghei–infected mice
there was a steady and significant decline in total and bioac-
tive TGF-b production from day 10 after infection on-
wards (day 0 versus day 20, total TGF-b student’s t test (t)
5 7.47, degrees of freedom (df) 5 8, P ,0.001; bioactive
TGF-b t 5 81.7, df 5 8, P ,0.0001), with levels of TGF-b
being inversely related to parasitemia (Fig. 1 a). In both P.
chabaudi chabaudi– and P. yoelii–infected mice there was a
transient fall in bioactive TGF-b production as parasitemia
increased; this was statistically significant for P. chabaudi cha-
baudi at day 7 (t 5 3.77, df 5 8, P 5 0.005) and for P. yoelii
at day 12 (t 5 4.99, df 5 8, P 5 0.005), but total TGF-b
production increased steadily and significantly throughout
the course of infection (day 0 versus day 23, t .3.9, df 5 8,
P 5 0.004 in both cases; Fig. 1, b and c).
In a parallel experiment, levels of circulating serum
TGF-b1 in infected mice were measured by ELISA (Fig.
2). This assay measures both latent and bioactive TGF-b1.
In P. berghei–infected mice, plasma TGF-b1 levels declined
significantly between days 8 and 20 (t 5 6.3, df 5 7, P
,0.001). In contrast, plasma TGF-b1 levels in mice in-
fected with P. chabaudi chabaudi or P. yoelii decreased tran-
siently during the first week of infection (day 0 versus day
3, t 5 3.7, df 5 8, P 5 0.006 for P. chabaudi chabaudi; t 5
2.34, df 5 8, P ,0.049 for P. yoelii) but then rose steadily
for the remainder of the infection (day 0 versus day 20, t
.5.9, df 5 8, P ,0.001 in both cases).
Taken together, these data suggest that TGF-b may play
a crucial role in preventing the severe pathology of malaria.
Where TGF-b levels are maintained at normal or above
normal levels, the mice survive, but where TGF-b levels
are suppressed, the mice die.
The Role of TGF-b in Murine Malaria Infections
Neutralization of TGF-b. To test the hypothesis that
TGF-b is required to prevent the severe pathology associ-42 TGF-b and Malaria
ated with some murine malarias, mice were treated with a
neutralizing antibody to all mouse TGF-b isoforms imme-
diately before and during infection with P. berghei, P. cha-
baudi chabaudi, or P. yoelii. Anti–TGF-b antibody, or iso-
type-matched control IgG, was administered 1 d before
infection and on days 2, 5, and 7 after infection (Fig. 3).
In this experiment, P. berghei–infected mice received 105
infected erythrocytes, leading to death between days 10
and 13. Anti–TGF-b treatment significantly enhanced the
rate of increase P. berghei parasitemia (Fig. 3 a, treated ver-
sus untreated mice, day 7, t 5 10.2, df 5 8, P ,0.0001),
and all the infected mice died on either day 6 or 8 after in-
fection, 4 or 5 d earlier than in mice who received the con-
trol antibody (Fig. 3 d). The anti–TGF-b antibody did not,
by itself, cause any observable side-effects, as treated, unin-
fected mice remained perfectly healthy (data not shown).
Neutralization of TGF-b converted the normally nonle-
thal P. chabaudi chabaudi infection into a rapidly lethal infec-
tion. Infected mice began dying at day 6 after infection and
all died by day 12 (Fig. 3 e). Although parasitemia increased
more rapidly in anti–TGF-b–treated mice than in un-
treated mice (day 10, t 5 4.74, df 5 8, P ,0.001) and the
peak parasitemia occurred z2 d earlier in treated mice, the
peak was not significantly higher than in untreated mice
(Fig. 3 b; t 5 0.92, df 5 8, P 5 0.39).
In contrast, neutralization of TGF-b had little effect on
the overall course of P. yoelii infection. Parasitemia rose
slightly earlier in treated mice and was significantly higher
at day 12 (treated versus untreated, t 5 3.58, df 5 8, P 5
0.007), but the peak parasitemia was not significantly dif-
ferent (day 16, t 5 1.31, df 5 8, P 5 0.23). Parasitemia re-
solved spontaneously (Fig. 3 c) and all the mice survived
(Fig. 3 f).
These data show very clearly that TGF-b plays a crucial
role in protecting mice with P. chabaudi chabaudi infection
from the severe pathology of malaria and suggest that the
lack of a TGF-b response in mice infected with P. berghei
may explain the severe pathology associated with this para-
site. Interestingly, neutralization of TGF-b has little effect
on the outcome of P. yoelii infection, suggesting that this
parasite interacts very differently with the host’s immune
system compared with P. berghei or P. chabaudi chabaudi.
The data also suggest that TGF-b may contribute to the
Figure 1. TGF-b production by splenic mononuclear cells during mu-
rine malaria infections, measured by bioassay after 48 h in vitro culture.
Mice were infected with (a) 104 P. berghei–, (b) 105 P. chabaudi chabaudi–,
or (c) 105 P. yoelii–infected erythrocytes on day 0. n 5 5 mice/group; star,
no data; hatched bar, total TGF-b; dotted bar, bioactive TGF-b; black circle,
percentage of parasitemia.
Figure 2. Serum TGF-b1 levels in malaria-infected mice, measured by
ELISA. 5 mice/group. Mice were infected with (d) 104 P. berghei, (r)
105 P. yoelii, (j) 105 P. chabaudi chabaudi, or were left uninfected (h).43 Omer and Riley
control of parasite growth as, in all cases, neutralization of
TGF-b led to increased rates of parasite proliferation.
However, the effect of anti-TFG-b antibody on mouse
survival is probably distinct from its effect on parasitemia, as
parasitemia increased more rapidly in all infections, but (a)
death was accelerated only in P. berghei and P. chabaudi cha-
baudi infections and (b) P. chabaudi chabaudi–infected mice
died at parasitemias that are compatible with survival in
control mice.
Treatment of P. berghei–infected Mice with TGF-b1. To test
the hypothesis that the severity of P. berghei malaria in
BALB/c mice is associated with the failure to upregulate
TGF-b production during infection, mice were infected
with 105 P. berghei–infected erythrocytes and treated with
either 5 or 20 ng/mouse of rTGF-b1 daily for 5 d.
In mice receiving rTGF-b1, the parasitemia rose less
quickly than in control mice (Fig. 4 a). Importantly, death was
significantly delayed in treated mice; mice receiving 20 ng
TGF-b1 died 12 d later than untreated mice, whereas mice
receiving 5 ng/day died z20 d later (Fig. 4 b). However, it
was not possible to separate the effect of TGF-b on parasite
growth from the effect on mouse survival; in mice treated
with 20 ng rTGF-b, parasitemia rose more quickly, and
death occurred earlier, than in mice receiving 5 ng TGF-b.
Interaction between TGF-b and Other Cytokines
TNF-a and IFN-g. It is known that much of the pa-
thology of malaria is mediated by proinflammatory cyto-
kines such as TNF-a and IFN-g (25, 28, 29). TGF-b is a
known antiinflammatory agent that acts to downregulate
the production of proinflammatory cytokines (37). We hy-
pothesized that the severe pathology of P. berghei infection
was due to overproduction of proinflammatory cytokines in
the absence of TGF-b. Circulating levels of TNF-a and
IFN-g in the plasma of infected mice were measured by
ELISA.
In mice infected with P. berghei, serum TNF-a levels rise
significantly over the first 10 d of infection (Fig. 5 a; day 3
versus day 10, t 5 3.26, df 5 8, P 5 0.012). As predicted,
when P. berghei–infected mice are treated with rTGF-b,
there is a highly significant decrease in circulating levels of
TNF-a (Fig. 5 a; t .4.8, df 5 8, P ,0.001 at days 3, 7,
and 10), and when mice are given anti–TGF-b antibody,
Figure 3. Effect of treatment with anti–TGF-b monoclonal antibody (given on days 21, 2, 5, and 7 after infection) on the course of malaria para-
sitemia (mean % parasitemia 6 SD; a–c) and mouse survival (d–f) with (a and d) 105 P. berghei, (b and e) 105 P. chabaudi chabaudi, and (c and f) 105 P. yoelii.
d, anti–TGF-b–treated; s, control, treated with irrelevant IgG1.44 TGF-b and Malaria
serum TNF-a levels are significantly higher (day 7 after in-
fection, control mice, mean TNF-a 5 5.4 6 0.5 ng/ml;
anti–TGF-b mice, mean 5 9.15 6 0.92 ng/ml; t 5 7.92,
df 5 7, P ,0.0001).
In contrast, rTGF-b1 or anti–TGF-b antibody had an
unexpected effect on levels of circulating IFN-g in P.
berghei–infected mice. rTGF-b1 treatment lead to a small,
although statistically significant, increase in serum IFN-g
levels (Fig. 5 b), whereas anti–TGF-b antibody had no sig-
nificant effect on IFN-g levels (day 7 after infection, con-
trol mice, mean IFN-g 5 40.5 6 3.1 U/ml; anti–TGF-
b–treated mice, mean 5 44.3 6 2.25 U/ml; t 5 1.97, df 5 7,
P 5 0.1).
IL-4 and IL-10. An alternative means by which TGF-b
may downregulate inflammatory cytokines is by augmenta-
tion of the production of other antiinflammatory cytokines.
We therefore measured plasma levels of IL-4 and IL-10 in
P. berghei–infected mice and assessed the effect of rTGF-b
or anti-TGF-b antibody. Neither IL-4 nor IL-10 levels
changed significantly over the course of infection with P.
berghei (Fig. 5, c and d). Treatment with rTGF-b over 5 d
lead to an apparent steady decline in IL-4 levels (Fig. 5 c),
but the difference between the two groups was statistically
significant only on day 10 (t 5 3.7, df 5 8, P ,0.01). In
contrast, rTGF-b leads to a rapid and highly significant in-
crease in IL-10 production in infected mice (Fig. 5 d) that
persisted until at least day 10 after infection (days 3, 7, and
10, t .2.33, df 5 8, P ,0.05 in all cases). Anti–TGF-b an-
tibody treatment had no significant effect on IL-4 or IL-10
levels (data not shown).
In Vitro Induction of TGF-b by Live Malaria Parasites
The failure of mice infected with P. berghei to sufficiently
upregulate TGF-b production was investigated in vitro.
Plastic adherent splenic mononuclear cells from uninfected
mice were incubated in vitro for up to 36 h with parasit-
ized erythrocytes, uninfected erythrocytes, or mitogen, and
the concentration of total and bioactive TGF-b in the cul-
ture supernatants was measured by bioassay (Table 1).
The mitogen Con A induced production of TGF-b
within 2–6 h, and TGF-b levels peaked at 18 h. Live P.
chabaudi chabaudi parasites were almost as effective as Con
A, inducing TGF-b production within 6 h, with levels also
peaking after 18 h in culture. In contrast, P. berghei parasites
induced little if any TGF-b production.
Discussion
We have shown that murine infection with P. chabaudi
chabaudi or P. yoelii, but not P. berghei, is accompanied by
increased TGF-b production, as assessed by raised serum
levels of TGF-b1 in vivo and spontaneous secretion of
TGF-b in vitro by splenic mononuclear cells from infected
mice. We have also shown that TGF-b levels during mu-
rine malaria infection are inversely correlated with severity
of disease, in that lethal infections are accompanied by low
levels of TGF-b and self-resolving infections are accompa-
nied by high levels of TGF-b. These findings have been
confirmed by treatment of mice with either neutralizing
antibodies to TGF-b or rTGF-b1. These findings are con-
sistent with the only other data regarding TGF-b in mu-
rine malaria, which simply showed that P. berghei (ANKA)–
induced TGF-b mRNA levels were lower in susceptible
strains of mice than in resistant strains (13).
Given the wealth of evidence that the pathology of mu-
rine malaria is mediated by the inflammatory cytokines
IFN-g and TNF-a (2, 9, 11), the most likely explanation
for our observations was that TGF-b acted to downregu-
late either the production or the activity of these cytokines.
We were able to show quite clearly that rTGF-b1 treat-
ment led to a decrease in circulating levels of TNF-a but
had much less effect on levels of IFN-g. These observations
are consistent with the known targets of the antiinflamma-
tory activities of TGF-b, namely its ability to suppress
translation of TNF-a mRNA in macrophages (37) and to
inhibit transcription of genes for cytokines such as IL-8
Figure 4. Effect of treatment with rTGF-b1 on the course of P. berghei
parasitemia (a) and mouse survival (b). Mice were infected with 105 P.
berghei–infected erythrocytes and treated with 5 or 20 ng rTGF-b1 per
mouse daily for 5 d. d, 20 ng/d of rTGF-b1; j, 5 ng/d of rTGF-b1; s,
control, PBS-treated.45 Omer and Riley
(38) and macrophage chemoattractant protein (MCP1; 39).
In contrast, there is little evidence that TGF-b has a direct
effect on macrophage-derived IFN-g; rather, TGF-b an-
tagonizes the effects of IFN-g downstream of IFN-g itself,
for example by inhibiting the induction of MHC class II
expression (40).
Although our data are consistent with a direct effect of
TGF-b on TNF-a production, we cannot rule out an in-
direct effect via IL-10 (19, 20). IL-10 is induced by TGF-b
(19) and has been shown to suppress production of TNF-a
in activated macrophages (37). Consistent with this hy-
pothesis, IL-10 levels were not raised in the serum of P.
berghei–infected mice, but IL-10 was clearly upregulated
when infected mice were treated with rTGF-b1. A role for
IL-10 in ameliorating the pathology of P. chabaudi chabaudi
infection has been shown in IL-10–deficient mice (12) but,
interestingly, IL-10 does not seem to play a similar role in
avirulent P. yoelii or P. chabaudi adami infections where
IL-10–deficient mice were able to resolve their infections
normally (1). This mirrors our observation that the pathol-
ogy of P. yoelii was not affected by neutralization of TGF-b
activity and suggests that the pathology of P. yoelii infection
has a very different aetiology. However, IL-10 is unlikely
to be the only pathway for TGF-b activity as P. chabaudi
chabaudi infection is much more severe in mice treated with
anti–TGF-b antibody, where all the mice died, than in IL-
10–deficient mice, where mortality is restricted to female
mice and even then only 50% of the female mice die (12).
However, in both IL-10–deficient and anti–TGF-b–
treated mice, death occurs without a significant increase in
peak parasitemia, indicating that failure to control P. cha-
baudi chabaudi replication is not the cause of death. 
Our demonstration that TGF-b upregulates IL-10 pro-
duction without downregulating IFN-g offers an explana-
tion for the observation that both IFN-g and IL-10 levels
are raised in acute P. falciparum infection in humans (41).
Figure 5. Serum cytokine levels in P. berghei–infected (105 infected erythrocytes) mice, measured by ELISA. White bar, uninfected, control mice; dotted
bar, infected, untreated mice; black bar, infected mice treated with 20 ng of rTGF-b1 for 5 d. 46 TGF-b and Malaria
Little is known of TGF-b responses in human malarias; su-
pernatants of human mononuclear cells cocultured with P.
falciparum–infected erythrocytes contained high levels of
TGF-b (42), but TGF-b serum levels are lower in patients
with acute P. falciparum malaria than in healthy controls
(42a).
In addition to downregulation of TNF-a production,
TGF-b may inhibit the development of malarial pathology
by direct effects on parasite sequestration. Adherence of in-
fected erythrocytes to cerebral capillary endothelium, via
cellular adhesion molecules such as intercellular adhesion
molecule (ICAM)-1 and vascular cell adhesion molecule
(VCAM)-1, has been proposed to contribute to the devel-
opment of cerebral malaria (43, 44). Mice in which the
TGF-b1 genes have been disrupted show enhanced expres-
sion of both ICAM-1 and VCAM-1 (45), suggesting that
TGF-b may play a role in downregulating expression of
these adhesion molecules thus reducing the risk of cerebral
malaria.
Although our study provides strong evidence that TGF-b
can protect against the severe pathology of P. berghei and P.
chabaudi chabaudi malaria, our data also indicate that TGF-b
may play a role in controlling parasite growth, at least in
the early stages of infection, as anti–TGF-b antibody led to
more rapid parasite growth and a 5-d course of rTGF-b1
resulted in slower parasite growth. In the case of P. chabaudi
chabaudi infection, the effect of TGF-b on survival is clearly
distinct from its effect on parasite growth; this distinction is
less clear in P. berghei infection. The apparent ability of
TGF-b to help control parasite growth may relate to the
fact that, early in an immune response, low concentrations
of TGF-b actually promote inflammation, recruit mono-
cytes and macrophages to the site of injury, and activate
them to become phagocytic (15). In support of this hy-
pothesis, we have shown that TGF-b1 increases phagocy-
tosis of P. falciparum–infected erythrocytes by human pe-
ripheral blood mononuclear cells in vitro (Omer, F.M., and
E. Riley, manuscript in preparation). Thus, inhibition of
TGF-b early in the infection may inhibit macrophage acti-
vation and nonspecific parasite clearance, as has been
shown for other pathogens such as Candida albicans (46),
pneumococcus (47), and HIV (48). In contrast, high con-
centrations of TGF-b are antiinflammatory but also inhibit
the activity of inducible nitric oxide synthase (49), thus re-
ducing the ability of macrophages to control the growth of
intracellular pathogens such as Trypanosoma cruzi (50) and
Leishmania amazonensis (51). Thus, the balance between
controlling parasite replication and avoiding immunopa-
thology appears to depend on controlling local and sys-
temic concentrations of TGF-b.
In summary, the bimodal activities of TGF-b–promot-
ing inflammation and parasite clearance early in infection
while downregulating inflammation and pathology later in
infection—make it a very strong contender for being a ma-
jor immunoregulatory molecule, maintaining the balance
between the protective and pathogenic effects of other in-
flammatory cytokines during malaria infections. If this sup-
position is correct, one would predict that severe malaria in
humans is associated with reduced capacity to produce
TGF-b. Studies are currently underway in our laboratory
to test this hypothesis. However, this theory begs the ques-
tion as to why some infections are associated with low
TGF-b production. The preliminary data presented here,
indicating that P. berghei parasites fail to induce TGF-b
production from normal mouse macrophages, suggests that
genetic differences between parasites may be responsible.
Possible explanations for the failure of P. berghei to induce
TGF-b include the failure to induce TGF-b per se, induc-
Table 1. TGF-b Production by Splenic Adherent Mononuclear Cells (2 3 106/well) from Uninfected BALB/c Mice Incubated with Live 
Malaria Parasites (5 3 105/well)
TGF-b concentration (ng/ml)
0 h 2 h 6 h 10 h 18 h 36 h
Medium 0* 0 0 0.32 6 0.07 0.59 6 0.28 2.1 6 0.20
(1.23 6 0.08)‡ (2.91 6 1.05) (4.22 6 1.07)
mRBC 0 0 0 0.64 6 0.30 0.72 6 0.44 1.85 6 0.09
(1.40 10.09) (1.78 6 0.75) (3.82 6 1.95) (5.13 6 2.10)
Pb live 0 0 0.26 6 0.08 1.66 6 0.30 1.18 6 0.08 1.15 6 0.28
(2.01 6 0.90) (2.90 6 1.12) (3.11 6 1.41) (2.78 6 1.50)
Pc Live 0 0 0.66 6 0.07 1.4 6 0.07 4.6 6 0.53 5.4 6 1.12
(3.63 6 1.40) (6.23 6 1.40) (8.12 6 1.31) (7.93 6 2.03)
Con A 0 0.37 6 0.08 1.31 6 0.27 1.56 6 0.30 4.70 6 0.81 4.3 6 1.32
(1.40 6 0.34) (3.82 6 1.14) (7.36 11.82) (13.43 6 1.98) (11.07 6 2.34)
Results represent averages of data from three separate experiments. mRB, mouse erythrocytes, Pc, P. chabaudi, Pb, P. berghei.
*0 values represent below-detection limits of the bioassay.
‡Figures in parentheses represent TGF-b values determined for acid-activated sample supernatants.47 Omer and Riley
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